Potential of regulatory T-cell-based therapies in the management of severe COVID-19

"Cytokine storm", inflammation-mediated severe lung damage and defective haemostasis are the main underlying reasons for morbidity and mortality in coronavirus disease 2019 (COVID-19) patients [1]. Several immunotherapies that target various inflammatory processes have been successfully used in COVID-19 patients and many other strategies are under evaluation [2, 3]. However, in view of dysregulated immune responses in severe COVID-19 patients, we suggest that CD4+CD25+FoxP3+ regulatory T-cell (Treg)-based strategies could be considered for patient management.

Source: European Respiratory Journal - September 2, 2020 Category: Respiratory Medicine Authors: Stephen-Victor, E., Das, M., Karnam, A., Pitard, B., Gautier, J.-F., Bayry, J. Tags: Original Articles: Correspondence Source Type: research